A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.BackgroundThymic carcinoma (TC) is an exceptionally rare...